Tetratherix (ASX:TTX) said a Safety Review Committee confirmed that, to date, no procedural related adverse events were reported from the first patients, who were implanted with the company's Tutelix spacer, a device to reduce side effects from radiation therapy in prostate cancer, according to a Tuesday filing with the Australian bourse.

The prostate remained visible during the insertion of the spacer, which formed a hydrogel structure at the intended site, the filing said.

The presence of the spacer minimised the high dose received, and the size and the structure of the spacer remained unchanged during the treatment period, the filing added.

Patient recruitment is now underway for stage two of the company's Tutela trial, the company said.